TNB-486: An anti-CD19xCD3 T-cell Engager with a Better Therapeutic Window

Time: 12:00 pm
day: Day Two


  • TNB-486 is a novel anti-CD19xCD3 bispecific T-cell engager for the treatment of B-NHL
  • Preclinical data shows targeted lysis of CD19+ cells with minimal cytokine release, dose dependent clearance of CD19+ tumor cells in vivo, and favorable pharmacokinetics
  • TNB-486 has a better therapeutic window than first generation TCEs targeting CD19